Browse by Phase
Phase 1 Clinical Trials
Phase 1 trials test a new drug or treatment in a small group (20–80 people) for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects.
Total Trials
584
Recruiting Now
584
Top Conditions in Phase 1
Frequently Asked Questions — Phase 1 Trials
What is tested in a Phase 1 clinical trial?
Phase 1 trials test a new drug or treatment in a small group of 20–80 people for the first time. The primary goals are to evaluate safety, determine a safe dosage range, identify side effects, and study how the drug is metabolized and excreted. Phase 1 trials typically enroll patients with the target condition who have exhausted standard treatment options, or healthy volunteers in some cases.
How long do Phase 1 clinical trials last?
Phase 1 trials typically last several months to one year depending on the drug, dose-escalation protocol, and follow-up period. The relatively small patient cohort and focused safety objectives make Phase 1 the shortest stage in clinical development. Some are extended into Phase 1/2 combined designs to simultaneously gather early efficacy signals.
Are Phase 1 clinical trials safe to join?
Phase 1 trials are the first human tests of a new intervention and carry the most uncertainty about safety. All Phase 1 studies must be approved by an Institutional Review Board (IRB) and operate under strict FDA oversight. Participants receive intensive monitoring throughout the study. While risks exist, Phase 1 protocols use conservative dosing and frequent safety assessments to protect participants.
Active Phase 1 Studies
NCT07098052 Phase 1
Recruiting
A Study of HDM2020 in Patients With Advanced Solid Tumors
Condition
Solid Tumor
Enrollment
60 pts
Location
China
Sponsor
Hangzhou Zhongmei Huadong Phar
NCT06730386 Phase 1
Recruiting
A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors
Condition
Solid Cancer
Enrollment
100 pts
Location
Australia
Sponsor
Akeso
NCT06465069 Phase 1
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Canc...
Condition
Metastatic Solid Tumor
Enrollment
460 pts
Location
United States, Australia, China
Sponsor
Eli Lilly and Company
NCT07153172 Phase 1
Recruiting
Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108
Condition
Obesity
Enrollment
91 pts
Location
Canada
Sponsor
Novo Nordisk A/S
NCT07729839 Phase 1
Recruiting
Safety, Tolerability, and Pharmacokinetic Evaluation of ADB116 for Injection
Condition
Healthy Adult Participants
Enrollment
34 pts
Location
China
Sponsor
Jiangsu Aidea Pharmaceutical G
NCT04928677 Phase 1
Recruiting
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have ...
Condition
Primary Extra-cranial Solid Tumor
Enrollment
50 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT07060209 Phase 1
Recruiting
Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy ...
Condition
Healthy Volunteers
Enrollment
14 pts
Location
Vietnam
Sponsor
Haiphong University of Medicin
NCT07010432 Phase 1
Recruiting
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Condition
Obesity
Enrollment
144 pts
Location
Denmark
Sponsor
Novo Nordisk A/S
NCT07444398 Phase 1
Recruiting
Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Gu...
Condition
Decompensated Heart Failure
Enrollment
130 pts
Location
Pakistan
Sponsor
Khawaja Danish Ali
NCT07478848 Phase 1
Recruiting
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Condition
Large B Cell Lymphoma
Enrollment
14 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn
NCT07594067 Phase 1
Recruiting
TCR1188-ABC Cells in KRAS-mutated Cancers
Condition
Cholangiocarcinoma
Enrollment
30 pts
Location
United States
Sponsor
University of Pennsylvania
NCT05112549 Phase 1
Recruiting
Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomen...
Condition
Leptomeningeal Disease
Enrollment
46 pts
Location
Germany
Sponsor
University Hospital Tuebingen
NCT02912897 Phase 1
Recruiting
Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autolog...
Condition
Multiple Sclerosis
Enrollment
7 pts
Location
France
Sponsor
Nantes University Hospital
NCT06736379 Phase 1
Recruiting
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in He...
Condition
Head and Neck Cancers- Squamous Cell
Enrollment
41 pts
Location
United States
Sponsor
VLP Therapeutics
NCT05940896 Phase 1
Recruiting
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid T...
Condition
Solid Tumor
Enrollment
24 pts
Location
China
Sponsor
RemeGen Co., Ltd.
NCT06655324 Phase 1
Recruiting
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B ...
Condition
Healthy
Enrollment
250 pts
Location
United States
Sponsor
Merck Sharp & Dohme LLC
NCT06597721 Phase 1
Recruiting
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Sel...
Condition
Advanced Solid Tumor
Enrollment
210 pts
Location
United States, Australia
Sponsor
Adcendo ApS
NCT06963814 Phase 1
Recruiting
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced So...
Condition
Advanced Cancer
Enrollment
252 pts
Location
China
Sponsor
HC Biopharma Inc.
NCT07919314 Phase 1
Recruiting
A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP...
Condition
Healthy Participants
Enrollment
40 pts
Location
Canada
Sponsor
Kyorin Pharmaceutical Co.,Ltd
NCT06257693 Phase 1
Recruiting
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Condition
Prostate Adenocarcinoma
Enrollment
45 pts
Location
United States
Sponsor
Alessa Therapeutics Inc.
NCT07731347 Phase 1
Recruiting
Two Different Therapeutic Interventions Applied During Blood Sampling in Childre...
Condition
Blood Sampling
Enrollment
105 pts
Location
Turkey (Türkiye)
Sponsor
Igdir University
NCT04837547 Phase 1
Recruiting
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
Condition
Neuroblastoma
Enrollment
24 pts
Location
United States
Sponsor
University of Florida
NCT07338838 Phase 1
Recruiting
To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Pa...
Condition
Advanced Malignant Tumors
Enrollment
66 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic
NCT07469085 Phase 1
Recruiting
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Phar...
Condition
Healthy Participants
Enrollment
60 pts
Location
China
Sponsor
Shanghai Synvida Biotechnology
NCT07018518 Phase 1
Recruiting
PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Ca...
Condition
Hepatocellular Carcinoma
Enrollment
25 pts
Location
China
Sponsor
Chinese PLA General Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology